Read More: GRCE Stock On Track For Worst Week In 5.5 Years \u2014 What\u2019s Driving The Selloff?<\/a><\/p>\n For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n
An EMA committee has recommended the approval of ARWR\u2019s Redemplo to reduce triglyceride levels in adult patients with a rare disease called familial chylomicronemia syndrome. <\/p>\n
The European Commission is now expected to have a decision on the company\u2019s application for Redemplo by the second quarter of 2026.Earlier this week, Morgan Stanley upgraded Arrowhead to \u2018Overweight\u2019 from \u2018Equal Weight\u2019 with a price target of $100, up from $78.According to data from Koyfin, 10 of 12 analysts rated the stock \u2018Buy\u2019 or higher, two rated it \u2018Hold.\u2019<\/p>\n
Shares of Arrowhead Pharmaceuticals (ARWR) closed up 6% this week after the European Medicines Agency\u2019s (EMA) committee issued a positive opinion recommending approval of Redemplo for familial chylomicronemia syndrome, building on heightened Wall Street optimism earlier this week.<\/p>\n
ARWR stock has closed higher for six consecutive weeks as of Friday-end.<\/p>\n
What Drove The Rally This Week?<\/p>\n
Arrowhead said on Friday that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use has recommended the approval of the company\u2019s Redemplo to reduce triglyceride levels in adult patients with a rare disease called familial chylomicronemia syndrome, which is characterized by triglyceride levels that can be orders of magnitude higher than normal. Higher triglyceride levels can lead to a higher risk of developing acute, recurrent, and potentially fatal pancreatitis.<\/p>\n
The European Commission is now expected to have a decision on the company\u2019s application for Redemplo by the second quarter of 2026. The medicine is already approved in the United States, Canada, and China for the condition. Redemplo is self-administered via subcutaneous injection once every three months.<\/p>\n
Wall Street Optimism<\/p>\n
Earlier this week, Morgan Stanley upgraded Arrowhead to \u2018Overweight\u2019 from \u2018Equal Weight\u2019 with a price target of $100, up from $78. The firm sees the stock’s momentum continuing ahead of late-stage Severe Hypertriglyceridemia (sHTG) data due in Q3. Morgan Stanley expects positive data to “unlock a multibillion-dollar opportunity that remains underappreciated” at current share levels.<\/p>\n
BofA on Monday also raised the firm’s price target on Arrowhead to $93 from $81 and kept a \u2018Buy\u2019 rating on the shares. The firm’s raised target reflects a refined view of the Redemplo-sHTG total addressable market, as it now models $3 billion in peak sales versus $2.4 billion previously forecast, the analyst told investors.<\/p>\n
According to data from Koyfin, 10 of 12 analysts rated the stock \u2018Buy\u2019 or higher, two rated it \u2018Hold.\u2019 The stock has an average price target of $84.18, representing a potential upside of 14%.<\/p>\n
How Did Retail Traders React?<\/p>\n
On Stocktwits, retail sentiment around ARWR stock rose from \u2018bullish\u2019 to \u2018extremely bullish\u2019 territory over the past 24 hours, while message volume stayed at \u2018high\u2019 levels.<\/p>\n
A Stocktwits user voiced optimism for the impending drug approval in Europe.<\/p>\n
ARWR stock<\/a> has rallied about 454% over the past 12 months.\u00a0<\/p>\n Read More: GRCE Stock On Track For Worst Week In 5.5 Years \u2014 What\u2019s Driving The Selloff?<\/a><\/p>\n For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n
![\"Follow](\"https:\/\/chunks-prd.stocktwits-cdn.com\/_next\/static\/media\/google-news-icon.d9c2bfd1.svg\"\/){kind=icon}
<\/a><\/p>\n